Financhill
Buy
61

SLNO Quote, Financials, Valuation and Earnings

Last price:
$50.34
Seasonality move :
14.72%
Day range:
$48.64 - $50.49
52-week range:
$36.61 - $60.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,547.46x
P/B ratio:
9.29x
Volume:
749.8K
Avg. volume:
529.4K
1-year change:
14.2%
Market cap:
$2.3B
Revenue:
--
EPS (TTM):
-$4.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SLNO
Soleno Therapeutics
-- -- -- -- $74.25
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
CVM
CEL-SCI
-- -- -- -- $7.40
IGC
IGC Pharma
$204K -$0.03 3.39% -50% $3.88
KRYS
Krystal Biotech
$91.4M $1.85 121.14% 497.44% $214.80
LEGN
Legend Biotech
$179M -$0.38 104.21% -8.33% $77.92
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SLNO
Soleno Therapeutics
$49.63 $74.25 $2.3B -- $0.00 0% 2,547.46x
AIM
AIM ImmunoTech
$0.12 $2.75 $7.6M -- $0.00 0% 32.98x
CVM
CEL-SCI
$0.28 $7.40 $21.9M -- $0.00 0% --
IGC
IGC Pharma
$0.32 $3.88 $25.5M -- $0.00 0% 18.82x
KRYS
Krystal Biotech
$186.89 $214.80 $5.4B 62.51x $0.00 0% 19.10x
LEGN
Legend Biotech
$37.94 $77.92 $7B -- $0.00 0% 11.06x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SLNO
Soleno Therapeutics
-- -0.316 -- --
AIM
AIM ImmunoTech
48.41% 1.568 17.25% 0.71x
CVM
CEL-SCI
-- 1.534 -- --
IGC
IGC Pharma
2.1% -1.752 0.51% 0.21x
KRYS
Krystal Biotech
-- 2.518 -- 6.89x
LEGN
Legend Biotech
22.45% 1.943 5.04% 4.49x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SLNO
Soleno Therapeutics
-- -$58.8M -- -- -- -$24M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CVM
CEL-SCI
-- -$6.9M -- -- -- -$4.2M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
KRYS
Krystal Biotech
$86.2M $41.4M 10.49% 10.49% 45.4% $52M
LEGN
Legend Biotech
$112.6M -$74.4M -12.31% -15.44% 24.48% -$84.5M

Soleno Therapeutics vs. Competitors

  • Which has Higher Returns SLNO or AIM?

    AIM ImmunoTech has a net margin of -- compared to Soleno Therapeutics's net margin of -10571.43%. Soleno Therapeutics's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About SLNO or AIM?

    Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 2191.67%. Given that AIM ImmunoTech has higher upside potential than Soleno Therapeutics, analysts believe AIM ImmunoTech is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is SLNO or AIM More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

  • Which is a Better Dividend Stock SLNO or AIM?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or AIM?

    Soleno Therapeutics quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Soleno Therapeutics's net income of -$56M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 32.98x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,547.46x -- -- -$56M
    AIM
    AIM ImmunoTech
    32.98x -- $35K -$3.7M
  • Which has Higher Returns SLNO or CVM?

    CEL-SCI has a net margin of -- compared to Soleno Therapeutics's net margin of --. Soleno Therapeutics's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    CVM
    CEL-SCI
    -- -$0.11 --
  • What do Analysts Say About SLNO or CVM?

    Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand CEL-SCI has an analysts' consensus of $7.40 which suggests that it could grow by 2504.72%. Given that CEL-SCI has higher upside potential than Soleno Therapeutics, analysts believe CEL-SCI is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is SLNO or CVM More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.414%.

  • Which is a Better Dividend Stock SLNO or CVM?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or CVM?

    Soleno Therapeutics quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Soleno Therapeutics's net income of -$56M is lower than CEL-SCI's net income of -$7.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,547.46x -- -- -$56M
    CVM
    CEL-SCI
    -- -- -- -$7.1M
  • Which has Higher Returns SLNO or IGC?

    IGC Pharma has a net margin of -- compared to Soleno Therapeutics's net margin of -711.67%. Soleno Therapeutics's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About SLNO or IGC?

    Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1110.94%. Given that IGC Pharma has higher upside potential than Soleno Therapeutics, analysts believe IGC Pharma is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is SLNO or IGC More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

  • Which is a Better Dividend Stock SLNO or IGC?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or IGC?

    Soleno Therapeutics quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. Soleno Therapeutics's net income of -$56M is lower than IGC Pharma's net income of -$1.8M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 18.82x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,547.46x -- -- -$56M
    IGC
    IGC Pharma
    18.82x -- $257K -$1.8M
  • Which has Higher Returns SLNO or KRYS?

    Krystal Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 49.9%. Soleno Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 10.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    KRYS
    Krystal Biotech
    94.57% $1.52 $946.4M
  • What do Analysts Say About SLNO or KRYS?

    Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand Krystal Biotech has an analysts' consensus of $214.80 which suggests that it could grow by 14.93%. Given that Soleno Therapeutics has higher upside potential than Krystal Biotech, analysts believe Soleno Therapeutics is more attractive than Krystal Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    KRYS
    Krystal Biotech
    8 1 0
  • Is SLNO or KRYS More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.951%.

  • Which is a Better Dividend Stock SLNO or KRYS?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or KRYS?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $91.1M. Soleno Therapeutics's net income of -$56M is lower than Krystal Biotech's net income of $45.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 62.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 19.10x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,547.46x -- -- -$56M
    KRYS
    Krystal Biotech
    19.10x 62.51x $91.1M $45.5M
  • Which has Higher Returns SLNO or LEGN?

    Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    LEGN
    Legend Biotech
    60.37% $0.14 $1.3B
  • What do Analysts Say About SLNO or LEGN?

    Soleno Therapeutics has a consensus price target of $74.25, signalling upside risk potential of 49.61%. On the other hand Legend Biotech has an analysts' consensus of $77.92 which suggests that it could grow by 105.37%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    LEGN
    Legend Biotech
    11 2 0
  • Is SLNO or LEGN More Risky?

    Soleno Therapeutics has a beta of -1.695, which suggesting that the stock is 269.471% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or LEGN?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or LEGN?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 2,547.46x versus 11.06x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    2,547.46x -- -- -$56M
    LEGN
    Legend Biotech
    11.06x -- $186.5M $26.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock